特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

新型コロナウイルス感染症によるマルチプレックス症候性診断市場への影響:戦略と動向、症候性・国別の予測、市場分析、エグゼクティブガイド(2020年~2024年)

Syndromic Multiplex Diagnostic Markets with Covid-19 Impact. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Country. with Market Analysis, Executive Guides and Customization. 2020 to 2024

発行 Howe Sound Research 商品コード 939942
出版日 ページ情報 英文 399 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.98円で換算しております。
新型コロナウイルス感染症によるマルチプレックス症候性診断市場への影響:戦略と動向、症候性・国別の予測、市場分析、エグゼクティブガイド(2020年~2024年) Syndromic Multiplex Diagnostic Markets with Covid-19 Impact. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Country. with Market Analysis, Executive Guides and Customization. 2020 to 2024
出版日: 2020年06月02日 ページ情報: 英文 399 Pages
概要

当レポートは新型コロナウイルス感染症によるマルチプレックス症候性診断市場への影響について調査しており、市場の動向や開発、成長および抑制要因、競合情勢、症候性・場所・地域別の市場分析、主要企業における最近の進展等の情報を提供しています。

目次

市場ガイド

  • 状況分析と新型コロナウイルス感染症の影響の概要
  • エグゼクティブおよびマーケティングスタッフ向けガイド
  • 投資アナリストと経営コンサルタントのためのガイド
  • 主要企業の市場シェア

第1章 イントロダクション・市場の定義

第2章 感染症:病原体ガイド

  • コロナウイルス
    • 重症急性呼吸器症候群(SARS)
    • 中東呼吸器症候群(MERS)
    • COVID-19(新型コロナウイルス感染症)SARS CoV 2ウイルス
  • HIV-ヒト免疫不全ウイルス(AIDS)
    • ウイルス学
    • 診断
    • 検査
  • HBV-B型肝炎
    • ウイルス学
    • メカニズム
    • 診断
    • 市場機会分析
  • HCV-C型肝炎
    • 分類
    • 分子生物学
    • レプリケーション
    • 遺伝子型
    • 市場機会分析
  • HPV-ヒトパピローマウイルス
    • ウイルス学
    • 診断
    • 市場機会分析
  • インフルエンザ
    • ウイルス学
    • 検査
    • 市場機会分析
  • CTGC-クラミジア/淋病
    • 淋病
    • クラミジア
    • 検査
    • 市場機会分析
  • 結核
    • マイコバクテリア
    • 診断
    • 疫学
    • 分子診断検査
    • 市場機会分析
  • MRSA-メチシリン耐性黄色ブドウ球菌
    • 診断
    • FDA承認分子検査
    • 市場機会分析
  • VRE-バンコマイシン耐性腸球菌
    • FDAによるVREのMDx検査の承認
    • 市場機会分析

第3章 業界の概要

  • 業界参入者
    • IVDサプライヤー
    • 独立ラボ:専門/特殊検査
    • 独立ラボ:国/地域
    • 独立ラボ:分析
    • 公立国立/地域ラボ
    • 病院のラボ
    • 医師のラボ
    • 監査機関
  • 臨床検査室の市場セグメンテーション
    • 従来の市場セグメンテーション
    • ラボ・焦点とセグメンテーション
    • 症候群の検査市場セグメント
  • 産業構造
    • 病院検査シェア
    • 規模の経済
    • 内科医院
    • 医師・POCT

第4章 市場動向

  • 成長要因
  • 抑制要因
  • 計装と自動化
  • 診断技術開発

第5章 症候性検査:最近の進展

  • 主な症候性検査企業のプロファイル
  • Abbott Diagnostics (Alere)
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diasorin
  • Expedeon
  • Fusion Genomics.
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veramarx
  • XCR Diagnostics

第6章 世界市場

  • 国別:世界市場概要
    • チャート
  • 症候性別
  • 場所別

第7章 世界市場:症候性別

  • 呼吸器
  • 胃腸
  • 血液
  • 髄膜炎/脳炎
  • 性感染症
  • その他

第8章 世界市場:場所別

  • 病院ラボ
  • 外来ラボ
  • POC
  • その他

付録

  • 米国のメディケアシステム:2020年臨床検査料のスケジュール
  • 新型コロナウイルス感染症承認済みアッセイ
図表

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 3 Characteristics of Coronavirus Pandemic Infections
  • Table 4 COVID-19 Symptoms
  • Table 5 Classification of HIV Species
  • Table 6 HBV Tests - CMS Codes & Prices
  • Table 7 HCV Tests - CMS Codes & Prices
  • Table 8 HPV Clearance Rates
  • Table 9 HPV Tests - CMS Codes & Prices
  • Table 10 HPV Tests, Technology, Types
  • Table 11 Types of Influenza Tests
  • Table 12 Influenza Tests - CMS Codes & Prices
  • Table 13 FDA Cleared Molecular Assays for Influenza
  • Table 14 FDA Cleared NAAT CTGC Tests
  • Table 15 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 16 Influenza Tests - CMS Codes & Prices
  • Table 17 FDA Approved MDx Tests for Tuberculosis
  • Table 18 Tuberculosis Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for MRSA
  • Table 20 MRSA Tests - CMS Codes & Prices
  • Table 21 FDA Approved Tests for VRE
  • Table 22 VRE Tests - CMS Codes & Prices
  • Table 23 FDA Approved Tests for VRE
  • Table 24 VRE Tests - CMS Codes & Prices
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Possible Market Segments of Syndromic Multiplex Market
  • Table 30 Five Factors Driving Growth
  • Table 31 How SMT Improves Outcomes
  • Table 32 Four Factors Limiting Growth
  • Table 33 - Global Market by Region
  • Table 34 Global Market by Syndrome
  • Table 35 Global Market by Place
  • Table 36 Respiratory by Country
  • Table 37 Gastrointestinal by Country
  • Table 38 Blood by Country
  • Table 39 Meningitis/Encephalitis by Country
  • Table 40 Sexually Transmitted Disease by Country
  • Table 41 Other by Country
  • Table 42 Hospital Lab by Country
  • Table 43 Outpatient Lab by Country
  • Table 44 POC by Country
  • Table 45 Other by Country
  • Table 46 2020 Clinical Lab Fee Schedule
  • Table 47 COVID -19 Approved Assays

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • FIGURE 3 STRUCTURE OF CORONAVIRUSES
  • Figure 4 HIV Virion
  • Figure 5 Diagram of the HIV Replication Cycle
  • Figure 6 The Structure of the HBV Virus
  • Figure 7 Hepatitis B Replication
  • Figure 8 Structure of the HCV Virus
  • Figure 9 HCV Replication Cycle
  • Figure 10 Structure of the Influenza Virion
  • Figure 11 Influenza Replication
  • Figure 12 Scanning Electronmicrograph of Tuberculosis
  • Figure 13 Chart Death Rates and Infectious Disease Decline
  • Figure 14 Comparing Syndromic and Targeted Testing
  • Figure 15 The Multiplex Paradigm Shift
  • Figure 16 Global Market Density Chart
  • Figure 17 Global Market by Syndrome - Base vs. Final
  • Figure 18 Global Market by Syndrome Base Year
  • Figure 19 Global Market by Syndrome End Year
  • Figure 20 Syndrome Share by Year
  • Figure 21 Syndrome Segments Growth
  • Figure 22 Global Market by Place - Base vs. Final
  • Figure 23 Global Market by Place Base Year
  • Figure 24 Global Market by Place End Year
  • Figure 25 Place Share by Year
  • Figure 26 Place Segments Growth
  • Figure 27 Respiratory Growth
  • Figure 28 Gastrointestinal Diagnostics Growth
  • Figure 29 Blood Growth
  • Figure 30 Meningitis/Encephalitis Growth
  • Figure 31 Sexually Transmitted Disease Growth
  • Figure 32 Other Growth
  • Figure 33 Hospital Lab Growth
  • Figure 34 Outpatient Lab Growth
  • Figure 35 POC Growth
  • Figure 36 Other Growth
目次

OVERVIEW:

How will COVID-19 affect Syndromic and Infectious Disease Diagnostics? The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2024. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis & COVID Impact Overview
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants
  • iD. Market Shares of Leading Companies - Table and Chart

1. Introduction and Market Definition

  • 1.1 What are Syndromic Multiplex Tests?
  • 1.2 Syndromic Testing - the quiet revolution in diagnostics
    • 1.2.1 Syndromic Testing - more than Panels.
  • 1.3 Market Definition
    • 1.3.1 Multiplex Market Size
    • 1.3.2 Panel Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Guide to the Pathogens

  • 2.0 The Coronavirus
    • 2.0.1 Severe acute respiratory syndrome (SARS)
    • 2.0.2 Middle East respiratory syndrome (MERS)
    • 2.0.3 COVID-19. The SARS CoV 2 Virus
      • 2.0.3.1 Signs and symptoms
      • 2.0.3.2 Transmission
      • 2.0.3.3 Diagnosis
      • 2.0.3.4 Prevention
      • 2.0.3.5 Management
      • 2.0.3.6 Prognosis
  • 2.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 2.1.1 Virology
      • 2.1.1.1 Classification
      • 2.1.1.2 Structure and genome
      • 2.1.1.3 Tropism
      • 2.1.1.4 Replication cycle
      • 2.1.1.5 Genetic variability
    • 2.1.2 Diagnosis
    • 2.1.3 Testing
      • 2.1.3.1 Antibody tests
      • 2.1.3.2 Point of Care Tests (POCT)
      • 2.1.3.4 Antigen Tests
      • 2.1.3.5 Nucleic acid-based tests (NAT)
      • 2.1.3.6 Other tests used in HIV treatment
  • 2.2 HBV - Hepatitis B
    • 2.2.1 Virology
      • 2.2.1.1 Genome
      • 2.2.1.2 Pathogenesis
      • 2.2.1.3 Hepatitis B virus replication
      • 2.2.1.4 Serotypes and genotypes
    • 2.2.2 Mechanisms
    • 2.2.3 Diagnosis
    • 2.2.4 Market Opportunity Analysis
  • 2.3 HCV - Hepatitis C
    • 2.3.1 Taxonomy
      • 2.3.2.1 Structure
      • 2.3.2.2 Genome
    • 2.3.3 Molecular biology
    • 2.3.4 Replication
    • 2.3.5 Genotypes
      • 2.3.5.1 Clinical importance
    • 2.3.6 Market Opportunity Analysis
  • 2.4 HPV - Human papillomavirus
    • 2.4.1 Virology
      • 2.4.1.1 E6/E7 proteins
      • 2.4.1.2 Role in cancer
      • 2.4.1.3 E2 research
      • 2.4.1.4 Latency period
      • 2.4.1.5 Clearance
    • 2.4.2 Diagnosis
      • 2.4.2.1 Cervical testing
      • 2.4.2.2 Oral testing
      • 2.4.2.3 Testing men
      • 2.4.2.4 Other testing
    • 2.4.3 Market Opportunity Analysis
  • 2.5 Influenza
    • 2.5.1 Virology
      • 2.5.1.1 Types of virus
      • 2.5.1.2 Influenzavirus A
      • 2.5.1.3 Influenzavirus B
      • 2.5.1.4 Influenzavirus C
      • 2.5.1.5 Structure, properties, and subtype nomenclature
      • 2.5.1.6 Replication
    • 2.5.2 Testing
      • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 2.5.3 Market Opportunity Analysis
  • 2.6 CTGC - Chlamydia/Gonorhea
    • 2.6.1 Gonorrhea
      • 2.6.1.1 Diagnosis
      • 2.6.1.2 Screening
    • 2.6.2 Chlamydia
      • 2.6.2.1 Diagnosis
      • 2.6.2.2 Screening
    • 2.6.3 Testing
      • 2.6.3.1 Nucleic acid amplification tests (NAATs).
      • 2.6.3.2 Performance of NAAT Tests
    • 2.6.4 Market Opportunity Analysis
  • 2.7 Tuberculosis
    • 2.7.1 Mycobacteria
    • 2.7.2 Diagnosis
      • 2.7.2.1 Active tuberculosis
      • 2.7.2.2 Latent tuberculosis
    • 2.7.3 Epidemiology
    • 2.7.4 Molecular Diagnostic Tests
    • 2.7.5 Market Opportunity Analysis
  • 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 2.8.1 Diagnosis
    • 2.8.2 FDA Approved Molecular Tests
    • 2.8.3 Market Opportunity Analysis
  • 2.9 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis
  • 2.10 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis

3. Industry Overview

  • 3.1 Industry Participants
    • 3.1.1 IVD Supplier
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 Audit body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
    • 3.2.3 Segmenting the Syndromic Testing Market
  • 3.3 Industry Structure
    • 3.3.1 Hospital Testing Share
    • 3.3.2 Economies of Scale
      • 3.3.2.1 Hospital vs. Central Lab
    • 3.3.3 Physician Office Lab's
    • 3.3.4 Physician's and POCT

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Speed of Diagnosis
    • 4.1.2 Effect of Syndromic Testing on Costs.
    • 4.1.3 Point of Care Advantage.
    • 4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
    • 4.1.5 Single Visits
    • 4.1.6 Improvement in Outcomes.
    • 4.1.7 Impact of the COVID-19 Pandemic.
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower Prices
    • 4.2.2 Administration/reimbursement
    • 4.2.3 Infectious Disease is Declining But....
    • 4.2.4 Wellness Hurts
    • 4.2.5 Economic Growth improves Living Standards
    • 4.2.6 Impact of the Pandemic Recession
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 The Shrinking Machine.
    • 4.3.3 Syndrome Testing Moving to Big Instruments?
  • 4.4 Diagnostic Technology Development
    • 4.4.1 Comparing Syndrome and Targeted Testing
    • 4.4.2 The Multiplex Paradigm Shift
    • 4.4.2 The Sepsis Testing Market - Bellwether for Syndromics
    • 4.4.3 The Single Visit and AntiMicrobial Resistance
    • 4.4.4 Syndromics drives POCT adoption
    • 4.4.5 A Big Future for PCR?

5. Syndromic Testing Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • ChromaCode Raises Additional $10M
  • COVID-19 Patients Need Syndromic Testing
  • GenMark Diagnostics - New Respiratory Panel due in June
  • Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • Exact Diagnostics launches respiratory panel control
  • bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • Nanomix Receives CE Mark for Diagnostic
  • Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • QIAGEN's New GI Panel Performance Assessed
  • McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • Applied BioCode Obtains FDA Clearance
  • Meridian Bioscience to Acquire GenePOC Inc
  • Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • Qiagen gets FDA clearance for syndromic testing system
  • Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • QuantuMDx and Molbio announce MoU
  • Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • Mobidiag Inks European, Middle Eastern Distribution Deals
  • BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial
  • 5.1 Profiles of Key Syndromic Testing Companies
  • Abbott Diagnostics (Alere)
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akkoni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Biocartis
  • BioFire Diagnostics
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Cue Health
  • Curetis
  • Diagenode Diagnostics
  • Diasorin
  • Expedeon
  • Fusion Genomics.
  • GenePOC Diagnostics
  • Genetic Signatures
  • GenMark Dx
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Janssen Diagnostics
  • Karius
  • Lexigene
  • Luminex
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen (Statdx)
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Saw Diagnostics
  • Seegene
  • Sensovation
  • Siemens Healthineers (Fast Track Diagnostics)
  • SkylineDx
  • Sona Nanotech
  • T2 Biosystems
  • Thermo Fisher
  • Veramarx
  • XCR Diagnostics

6. The Global Market for Syndromic Multiplex Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Syndrome - Overview
    • 6.2.1 Table - Global Market by Syndrome
    • 6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Syndrome - Base Year
    • 6.2.4 Chart - Global Market by Syndrome - End Year
    • 6.2.5 Chart - Global Market by Syndrome - Share by Year
    • 6.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 6.3 Global Market by Place - Overview
    • 6.3.1 Table - Global Market by Place
    • 6.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Place - Base Year
    • 6.3.4 Chart - Global Market by Place - End Year
    • 6.3.5 Chart - Global Market by Place - Share by Year
    • 6.3.6 Chart - Global Market by Place - Segments Growth

7. Global Syndromic Multiplex Dx Markets - By Syndrome

  • 7.1 Respiratory
    • 7.1.1 Table Respiratory - by Country
    • 7.1.2 Chart - Respiratory Growth
  • 7.2 Gastrointestinal
    • 7.2.1 Table Gastrointestinal - by Country
    • 7.2.2 Chart - Gastrointestinal Growth
  • 7.3 Blood
    • 7.3.1 Table Blood - by Country
    • 7.3.2 Chart - Blood Growth
  • 7.4 Meningitis/Encephalitis
    • 7.4.1 Table Meningitis/Encephalitis - by Country
    • 7.4.2 Chart - Meningitis/Encephalitis Growth
  • 7.5 Sexually Transmitted Disease
    • 7.5.1 Table Sexually Transmitted Disease - by Country
    • 7.5.2 Chart - Sexually Transmitted Disease Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global Syndromic Multiples Dx Markets - by Place

  • 8.1 Hospital Lab
    • 8.1.1 Table Hospital Lab - by Country
    • 8.1.2 Chart - Hospital Lab Growth
  • 8.2 Outpatient Lab
    • 8.2.1 Table Outpatient Lab - by Country
    • 8.2.2 Chart - Outpatient Lab Growth
  • 8.3 POC
    • 8.3.1 Table POC - by Country
    • 8.3.2 Chart - POC Growth
  • 8.4 Other Technology
    • 8.4.1 Table Other - by Country
    • 8.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
  • II. COVID-19 Approved Assays